Friday, 12 August 2011

Draft NICE guidance would deny up to 5,500 people with MS a valuable extra treatment option

Source: MS Trust
MS Trust is disappointed that draft guidance from NICE recommends that fingolimod (licensed under the Novartis owned trade name of Gilenya) should not be made automatically available to people with multiple sclerosis on the NHS.   Read full article here.